What We Offer

At MitoGENE, we partner with formulation companies, pharmaceutical manufacturers, and research institutions to provide access to high-quality Active Pharmaceutical Ingredients (APIs) sourced from reliable Indian producers.

We facilitate access to finished dosage forms—including tablets, capsules, and injectables—manufactured by WHO-GMP certified facilities and approved by CDSCO (India) for both domestic and international markets. Our portfolio primarily focuses on oncology, rare diseases, immunotherapy, and other complex therapeutic areas requiring specialized care.

Why Trust MitoGENE
  • Compliant & Certified Sourcing
    We work exclusively with audited API manufacturers in India, ensuring compliance with global regulatory standards and adherence to GMP guidelines.
  • Technical & Regulatory Documentation Support
    We provide the necessary dossiers and documentation—COA, MSDS, TSE/BSE, DMF (where available)—to support registration, regulatory submissions, or manufacturing use.
  • Competitive Pricing
    We negotiate on your behalf to secure cost-effective API options without compromising on quality—helping reduce manufacturing costs and maintain supply chain efficiency.
  • Therapeutic Range Diversity
    We offer a broad portfolio of APIs across major therapeutic classes with a focus on both specialty and high-demand molecules.
  • Reliable Logistics Network
    While MitoGENE does not handle import licensing or customs clearance, we coordinate with established logistics partners to ensure timely and safe delivery to your facility.
Therapeutic Focus Areas
  • Oncology APIs (e.g., Imatinib, Capecitabine, Gefitinib)
  • Cardiovascular & Diabetic Care
  • Antivirals & Anti-Infectives
  • CNS & Neurology
Our Promise to Our clients

At MitoGENE, we strive to be more than a supplier—we are a strategic access partner committed to providing authentic, compliant, and competitively priced APIs. We help manufacturers overcome sourcing challenges by bridging gaps in availability, documentation, and global regulatory requirements.